ALDARA SUMMARY
ALDARA™
[al dar' a]
(imiquimod)
Cream, 5%
Aldara ™ is the brand name for imiquimod which is an immune response modifier. Each gram of the 5% cream contains 50 mg of imiquimod in an off-white oil-in-water vanishing cream base consisting of isostearic acid, cetyl alcohol, stearyl alcohol, white petrolatum, polysorbate 60, sorbitan monostearate, glycerin, xanthan gum, purified water, benzyl alcohol, methylparaben, and propylparaben.
Aldara Cream is indicated for the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults.
Aldara Cream is indicated for the topical treatment of biopsy-confirmed, primary superficial basal cell carcinoma (sBCC) in immunocompetent adults, with a maximum tumor diameter of 2.0 cm, located on the trunk (excluding anogenital skin), neck, or extremities (excluding hands and feet), only when surgical methods are medically less appropriate and patient follow-up can be reasonably assured. The histological diagnosis of superficial basal cell carcinoma should be established prior to treatment, since safety and effectiveness of Aldara Cream have not been established for other types of basal cell carcinomas, including nodular, morpheaform (fibrosing or sclerosing) types.
Aldara Cream is indicated for the treatment of external genital and perianal warts/condyloma acuminata in individuals 12 years old and above.
|
ALDARA NEWS HIGHLIGHTS
Media Articles Related to Aldara (Imiquimod)
imiquimod-topical, Aldara
Source: MedicineNet Actinic Keratosis Specialty [2005.03.02]
August 2004
Source: Medscape Primary Care Headlines [2004.08.18]
Imiquimod, An Immune Response Modifier, Is Dependent On The OGF-OGFr Signaling Pathway
Source: Liver Disease / Hepatitis News From Medical News Today [2008.07.27]
Published Studies Related to Aldara (Imiquimod)
Treatment of vulvar intraepithelial neoplasia with topical imiquimod. [2008.04.03]
Imiquimod for treatment of vulvar and vaginal intraepithelial neoplasia. [2008.04]
Imiquimod 5% cream for treatment of HIV-negative Kaposi's sarcoma skin lesions: A phase I to II, open-label trial in 17 patients. [2008.04]
A randomized parallel study to assess the safety and efficacy of two different dosing regimens of 5% imiquimod in the treatment of superficial basal cell carcinoma. [2008]
Imiquimod 5% cream for treatment of HIV-negative Kaposi's sarcoma skin lesions: A phase I to II, open-label trial in 17 patients. [2007.12.06]
Clinical Trials Related to Aldara (Imiquimod)
A Phase II Study of Imiquimod 5 % Cream for the Treatment of Hemangioma in Infancy [Completed]
Aldara for the Treatment of Extensive Alopecia Areata [Completed]
Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Arms and Hands [Completed]
Topical Imiquimod for Bowen's Disease of the Head and Neck [Enrolling by invitation]
Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks [Enrolling by invitation]
|
